The unexpected outbreak of coronavirus disease (COVID 19) is projected to increase demand for hydroxychloroquine, which is anticipated to propel market expansion over the forecast period. For instance, on March 30, 2020, Novartis International AG declared that 30 million doses of hydroxychloroquine tablets were being shipped to the US Department of Health and Human Services (HHS) for carefully monitored clinical investigations. The goal of the study is to assess hydroxychloroquine's efficacy in treating individuals who have tested positive for coronavirus illness (COVID 19). The University of Washington received 20,000 doses of hydroxychloroquine from Sandoz on the same day for a COVID-19 PEP clinical investigation.
The projected size of the worldwide Hydroxychloroquine Market is US$ 484.9 million in 2019 and is anticipated to grow at a CAGR of 45.7% from 2020 to 2027.
Leading Companies in the Hydroxychloroquine Industry:
1. Sanofi S.A.: Sanofi S.A. is a multinational pharmaceutical company that engages in the research and development, of pharmacological products, in the prescription market. The firm cover therapeutic areas like Cardiovascular, central nervous system, diabetes, internal medicine. The company was founded in 973 and the headquarters are located in Paris, France. Products manufactured include Medications, Genetic drugs, Vaccines, Animal Health, etc. December, 2022 Sanofi expanded its collaboration with Innate Pharma, with Sanofi licensing a natural killer (NK) cell nagger program targeting B7H3 from Innate’s ANKET platform.
2. Amneal Pharmaceuticals, Inc: A producer of generic medications is Amneal Pharmaceuticals Inc. The reportable segments of the corporation include AvKARE, Specialty Products, and Generic Products. Created in 2002. Headquarters in the U.S. Amneal Pharmaceuticals, Inc. (the "Company") (NYSE: AMRX) and Kashiv BioSciences LLC ("Kashiv") today announced that Amneal Pharmaceuticals LLC ("Amneal"), a subsidiary of the Company, has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC ("Kashiv Specialty"), a wholly-owned subsidiary of Kashiv focused on the
3. Laurus Labs Limited: An Indian pharmaceutical firm called Laurus Labs Ltd. It offers contract research services, generic finished dosage forms (FDF), and active pharmaceutical ingredients (API) including intermediates. The company creates intermediates and APIs for a few high-growth antiretrovirals, hepatitis C, and oncology. Created in 2005. Telangana's capital is at Hyderabad.
4. Mylan N.V: Created to satisfy the rising need for potent medications, generic pharmaceutical goods are developed and manufactured. Built in 1961. With its corporate headquarters in the United Kingdom, Mylan and Upjohn, a division of Pfizer, will merge to become a new champion for global health that is specially positioned to meet the demand for medicine around the globe.
5. Zydus Pharmaceuticals, Inc.: Established in 2005. United States headquarters.Manufacturer and distributor of pharmaceutical goods and chemicals that support patients' efforts to treat and manage illnesses, combat infections, and enhance their general well-being. The company provides patients with top-notch healthcare solutions that enable them to live healthier and more fulfilling lives by providing calcium pills, salt injections, ointments, dinitrate tablets, paricalcitol capsules, and more.
6. Dr. Reddy's Laboratories: Established in 1984. Dr. Reddy's Laboratories is an Indian company with global operations that develops and produces generic pharmaceuticals. The business specialises in active pharmaceutical ingredients and low-cost, easily manufactured small-molecule generic medications. The most recent acquisitions are Habitrol (Dec 2014), Nimbus Health (Feb 2022), and Cidmus (Apr 2022).
7. Novartis International AG: Novartis AG is a Swiss pharmaceutical corporation founded in March 1996 by Johann Rudolf The headquarters are located in Basel Switzerland, Cambridge, The United States of America and Massachusetts. It is one of the largest Pharma based company incorporated. The drugs manufactured are sold worldwide. Total revenue earned as of 2022 is US 50.545 billion dollars. In June, 2022 Novartis completed the acquisition of Kedalion Therapeutics and its AcuStream technology.
Definition: Hydroxychloroquine is used to prevent and treat acute attacks of malaria in adults and children weighing more than 31 kg (68 lbs).
